However, because of the small number of human patients with PID, extensive genetic heterogeneity, and concurrent diseases and infections (viral meningitis, pneumococcal pneumonia and other recurring respiratory infections, asthma, skin infections, and renal disease), it is extremely difficult to separate secondary effects from primary cell autonomous effects of Hem-1 loss. This evidence concerns the gene NCKAP1L and pneumococcal pneumonia.